STOCK TITAN

PetVivo Holdings Inc - PETVW STOCK NEWS

Welcome to our dedicated news page for PetVivo Holdings (Ticker: PETVW), a resource for investors and traders seeking the latest updates and insights on PetVivo Holdings.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect PetVivo Holdings's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of PetVivo Holdings's position in the market.

Rhea-AI Summary
PetVivo Holdings, an emerging biomedical device company (NASDAQ: PETV & PETVW), will exhibit its lead product, Spryng with OsteoCushion Technology, at the Veterinary Meeting & Expo Conference from January 14th to 17th, 2024. The intra-articular injectable veterinary medical device is designed to manage joint-related afflictions such as osteoarthritis, and the company aims to network with industry leaders at the event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.5%
Tags
none
-
Rhea-AI Summary
PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) has entered into a definitive distribution agreement with Covetrus North America, LLC to market and promote its veterinary medical device, Spryng™ with OsteoCushion™ technology, throughout the United States. Covetrus sales and marketing activities will commence on January 1, 2024. This strategic partnership aims to benefit the veterinary industry, the veterinarians, the animals receiving Spryng, and the owners benefiting from the enhanced medical outcomes of their animals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.86%
Tags
none
-
Rhea-AI Summary
PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) achieved a significant milestone by distributing over 4500 syringes of Spryng™ with OsteoCushion™ technology to veterinarians in 2023. This represents a 60% increase from the previous year. The positive outcomes experienced by animals injected with Spryng have driven its momentum, with high enthusiasm from veterinarians and upcoming clinical studies and trade show exposure expected to further boost distribution in the new year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
41.46%
Tags
none
Rhea-AI Summary
PetVivo Holdings, Inc. (PETV & PETVW) achieves a significant milestone by selling its signature product Spryng™ with OsteoCushion™ Technology to over 600 veterinary clinics in 49 states.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.02%
Tags
none
-
Rhea-AI Summary
PetVivo Holdings, Inc. (PETV, PETVW) will be showcasing its lead product, SPRYNG™ with OsteoCushion™ Technology at the American Association Equine Practitioners conference, aiming to network with industry professionals and drive forward its innovative veterinary medical device. The conference will be held from November 29th to December 2nd, 2023 at the San Diego Convention Center in San Diego, California.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.49%
Tags
none
-
Rhea-AI Summary
PetVivo Holdings, Inc. (Nasdaq: PETV) announces financial results for the three months ended September 30, 2023. Key highlights include the release of clinical study results for Spryng™, raising $2.35 million from stock offerings, and entering into an ATM Sales Agreement with ThinkEquity, LLC.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.14%
Tags
earnings
Rhea-AI Summary
PetVivo Holdings, Inc. (NASDAQ: PETV and PETVW) will report financial results on November 14, 2023, after market close. The company will host a conference call to discuss these results at 4:00 p.m. CT (5:00 p.m. ET) on the same day. Attendees can register and access the webcast on PetVivo’s Investor Relations website. A replay of the webcast will be available through the same link. Participants can also access the call using the provided dial-in details.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.93%
Tags
earnings
-
Rhea-AI Summary
PetVivo Holdings, Inc. announced that two members of its Scientific/Veterinarian Team will present at the AAEP annual convention. Tom Yarbrough will discuss new classes of joint therapeutics, while Joseph Manning will talk about a novel collagen-elastin hydrogel microparticles biomaterial for joint conditions in equines. The presentations will take place from November 30th to December 2nd, 2023 in San Diego, California.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.18%
Tags
none
-
Rhea-AI Summary
PetVivo Holdings, Inc. received positive response for its innovative product Spryng™ with OsteoCushion™ technology at the ACVS conference. Two presentations and a clinical study demonstrated the benefits and tolerability of Spryng™ in managing joint-related afflictions in companion animals. The study showed significant improvements in pain, lameness, and quality of life scoring. Spryng™ is a non-invasive alternative for patients with cranial cruciate disease when surgery is not an option.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.63%
Tags
none
Rhea-AI Summary
PetVivo Holdings, Inc. to release results of clinical study at ACVS annual conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.31%
Tags
clinical trial
PetVivo Holdings Inc

Nasdaq:PETVW

PETVW Rankings

PETVW Stock Data

11.85M
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States
Minneapolis

About PETVW

petvivo, inc is an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices for pets, or pet therapeutics. petvivo believes that it can leverage the investments in the human biomaterials and medical device industries to commercialize therapeutics to pets in a capital and time efficient way. petvivo's strategy is to in-license proprietary products from human medical device companies specifically for use in pets. petvivo, inc, gel-del technologies, inc. and cosmetalife a corporation are all wholly-owned subsidiaries of petvivo holdings, inc.